Immunotherapy alone for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether using immunotherapy drugs (pembrolizumab or cemiplimab) alone, without chemotherapy, can treat advanced lung cancer in people with high PD-L1 levels. It is for people who have not yet received any treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- This is your first treatment for advanced lung cancer that has spread.
- Your lung cancer has a high PD-L1 level (at least 50%).
- Your cancer does not have EGFR, ALK, or ROS1 gene changes.
- You have not had immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
Hear when a new Non Small Cell Lung Cancer (Squamous or Non Squamous) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.